FDA lawyer explains reasoning behind size of penalty in landmark Abbott consent decree
This article was originally published in Clinica
The US FDA intended to send a message to other companies when it decided to impose a steep penalty on Abbott Laboratories, according to one of the US lawyers who worked on the case.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.